Search Results
Jul 31, 2025, 07:00 ET PreludeDx Study Demonstrates Superiority of DCISionRT® Over Clinicopathology Factors and Criteria for DCIS Treatment Management
Clinicopathologic Factors Alone in Predicting Radiation Benefit for Women with Low-Risk Ductal Carcinoma in Situ after Breast Conserving Surgery: The Impact of a 7-gene Biosignature based on 10-Year Ipsilateral Breast Recurrence (IBR) Rates" evaluated 10-year recurrence risk in 926 women diagnosed with DCIS and treated
More news about: PreludeDx
Jul 31, 2025, 07:00 ET Marengo Therapeutics Bolsters Advisory Strength with Appointment of Dr. Mikael Dolsten to its Board of Directors and Dr. Josep Tabernero to its Scientific Advisory Board
physician–scientist and biopharma leader, Dr. Dolsten has been instrumental in the development of breakthrough innovations spanning small molecules, biologics, gene therapies, and vaccines—including leading Pfizer's scientific response to the COVID-19 pandemic. His leadership has shaped portfolios at Boehringer
More news about: Marengo Therapeutics
Jul 31, 2025, 00:23 ET A PTC Therapeutics anuncia a aprovação do Sephience™ (sepiapterina) pela FDA para o tratamento de crianças e adultos que vivem com fenilcetonúria (PKU)
Sobre a fenilcetonúria A fenilcetonúria (PKU) é uma doença metabólica hereditária rara, que afeta o cérebro. É causada por um defeito no gene que ajuda a criar a enzima necessária para quebrar a fenilalanina (Phe). Se não for tratado ou mal administrado, o Phe - um aminoácido essencial encontrado
More news about: PTC Therapeutics, Inc.
Jul 30, 2025, 17:46 ET THR-β Agonist Market on the Rise: Insights and Projections Upto 2034 | DelveInsight
reduces inflammation, and suppresses fibrogenic pathways, mechanisms highly relevant to MASH therapy. Furthermore, THR‑β activation upregulates the ABCD2 gene, which encodes a compensatory peroxisomal transporter, offering therapeutic potential for rare genetic diseases like X‑ALD by lowering the accumulation
More news about: DelveInsight Business Research, LLP
Jul 30, 2025, 13:58 ET Everads Announces Two Oral Presentations at ASRS 2025, Including Full Clinical Trial Results with Its Novel Suprachoroidal Injector
developing this platform for in-office suprachoroidal buckling (viscopexy) to treat select retinal detachments. The company collaborates with partners across gene therapy, cell therapy, small molecule formulations, and other modalities to realize the full potential of its differentiated delivery approach.
More news about: Everads Therapy
Jul 30, 2025, 12:05 ET Sumitomo Pharma America Announces that the European Medicines Agency Has Granted Orphan Drug Designation to Nuvisertib (TP-3654) for the Treatment of Myelofibrosis
Switzerland GmbH) focused on addressing patient needs in oncology, urology, women's health, rare diseases, psychiatry & neurology, and cell & gene therapies. With several marketed products in the U.S., Canada, and Europe, and a diverse
More news about: Sumitomo Pharma America
Jul 30, 2025, 08:44 ET McGowan Acquires Aegis Professional Risk from K2 Insurance Services
diverse portfolio of companies. Gene and his team have a strong tradition of providing exemplary products and services to its clients… a tradition we intend to honor and continue." Please contact Brett Davis or Gene Mason with any questions:
More news about: The McGowan Companies
Jul 30, 2025, 08:30 ET How Cell-Free mRNA Templates Support Faster Research with High-Quality and Quick Turnaround, Upcoming Webinar Hosted by Xtalks
July 30, 2025 /PRNewswire/ -- mRNA has emerged as a powerful tool across vaccines, protein replacement therapies and gene editing. Central to these innovations is the need for ultra-fast, high-quality in vitro transcription (IVT) templates. Yet, researchers often
More news about: Xtalks
Jul 30, 2025, 08:03 ET MyHealthTeam Launches myMDteam Focused on Muscular Dystrophy
Symptoms include difficulty walking and running, frequent falls, shortness of breath, fatigue, and more. DMD is caused by a mutation of the dystrophy gene on the X chromosome, which results in a lack of the dystrophin protein. Without this protein, muscle cells begin to break down and are replaced by fatty
More news about: MyHealthTeam
Jul 30, 2025, 08:01 ET Lilly's Kisunla (donanemab-azbt) showed growing benefit over three years in early symptomatic Alzheimer's disease
any symptoms, but serious and life-threatening symptoms can occur. ARIA can be fatal. Carriers of one or two copies of the apolipoprotein E ε4 (ApoE4) gene may be at higher risk of developing Alzheimer's disease and experiencing ARIA. Patients should discuss any safety concerns with their healthcare providers. Kisunla
More news about: Eli Lilly and Company
Jul 30, 2025, 08:00 ET Orsini Selected as Specialty Pharmacy Partner for PTC Therapeutics' SEPHIENCE™ (sepiapterin)
possible." About Orsini Providing patients with comprehensive and compassionate care since 1987, Orsini is a leader in rare diseases and gene therapies. Orsini partners with biopharma innovators, healthcare providers and payors to support patients and their families in accessing revolutionary
More news about: Orsini
Jul 30, 2025, 08:00 ET CDI Labs Launches Pan-isotype Analysis of Serum Autoantibodies to Unlock Critical New Insights Into Humoral Immunity
clinical deployment phases, and include: autoantibody biomarker discovery and profiling; viral exposure profiling; immunogenicity assessment of cell, gene and radioligand therapies; antibody and ADC specificity profiling; target identification for monoclonals, biologics and drugs; and custom protein and
More news about: CDI LABORATORIES, INC.
Jul 29, 2025, 17:31 ET Triple-Negative Breast Cancer Market Gearing Up for Impressive Growth at a CAGR of 4.7% During the Forecast Period (2025-2034) | DelveInsight
recurrence, and unfavorable outcomes. TNBC tends to occur more frequently in younger women, individuals of African American descent, and those with BRCA1 gene mutations. The risk factors for TNBC are divided into two categories: non-modifiable factors, such as age, gender, genetic mutations, family
More news about: DelveInsight Business Research, LLP
Jul 29, 2025, 12:34 ET Hansa Biopharma announces key executive appointments to support continued growth
development program based on its proprietary IgG-cleaving enzyme technology platform, to address serious unmet medical needs in autoimmune diseases, gene therapy and transplantation. The company's portfolio includes imlifidase, a first-in-class immunoglobulin G (IgG) antibody-cleaving enzyme therapy,
More news about: Hansa Biopharma AB
Jul 29, 2025, 12:30 ET Hansa Biopharma announces key executive appointments to support continued growth
development program based on its proprietary IgG-cleaving enzyme technology platform, to address serious unmet medical needs in autoimmune diseases, gene therapy and transplantation. The company's portfolio includes imlifidase, a first-in-class immunoglobulin G (IgG) antibody-cleaving enzyme therapy,
More news about: Hansa Biopharma AB
Jul 29, 2025, 10:30 ET Cell Therapy Market to Reach USD 29.5 Billion by 2032, Growing at 21.5% CAGR | SkyQuest Technology Consulting
R&D around the world and advancements in genomics and cell manufacturing technologies are also promoting market development. Techniques such as CRISPR gene editing, induced pluripotent stem cells (iPSCs), and automated bioreactors have revolutionized the development pipeline. Government funding, public-private
More news about: SkyQuest Technology
Jul 29, 2025, 08:52 ET Athena Diagnostics Improves Ataxia Movement Disorder Testing with Novel Long-Read Gene Sequencing
test based on PacBio technology to improve carrier screening. In a study available as a preprint, a PureTarget gene panel was found to identify a specific repeating gene pattern associated with Spinocerebellar ataxia type 10 that may be associated with age of disease onset, information that
More news about: Quest Diagnostics
Jul 29, 2025, 08:45 ET Sarepta Therapeutics, Inc. Class Action: Levi & Korsinsky Reminds Sarepta Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of August 25, 2025 - SRPT
CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (i) ELEVIDYS, a prescription gene therapy for Duchenne, posed significant safety risks to patients; (ii) ELEVIDYS trial regimes and protocols failed to detect severe side effects; (iii)
More news about: Levi & Korsinsky, LLP
Jul 29, 2025, 08:33 ET Gridiron Coaches Foundation Announces Its Formation & Its Commitment to Supporting Former College Football Players Transition Into Coaching
coaches had on their players both on and off the field. The film highlights the unprecedented dynasty from Coach Bear Bryant, to Gene Stallings, and through Nick Saban's career at Alabama. "Playing under
More news about: Gridiron Coaches Foundation
Jul 29, 2025, 08:00 ET Kyowa Kirin Announces Abstract Presentation at the European Academy of Dermatology and Venereology (EADV) Congress
drug discovery and biotechnology innovation for more than 70 years and are currently working to engineer the next generation of antibodies and cell and gene therapies with the potential to help patients with high unmet medical needs, such as bone & mineral, intractable hematological diseases/hemato oncology,
More news about: Kyowa Kirin
Jul 29, 2025, 08:00 ET Kyowa Kirin Announces Abstract Presentation at the European Academy of Dermatology and Venereology (EADV) Congress
drug discovery and biotechnology innovation for more than 70 years and are currently working to engineer the next generation of antibodies and cell and gene therapies with the potential to help patients with high unmet medical needs, such as bone & mineral, intractable hematological diseases/hemato oncology,
More news about: Kyowa Kirin
Jul 29, 2025, 02:27 ET Tsingke Biotech Hosts 2025 Small Nucleic Acid Therapeutics Roundtable in Beijing
Biotech Tsingke Biotech is a synthetic biology and biotech manufacturing company focused on gene and nucleic acid technologies. The company provides a wide portfolio of services including gene synthesis, oligonucleotide production, RNA therapeutics support, and GMP-compliant raw material manufacturing
More news about: Beijing Tsingke Biotech Co., Ltd.
Jul 29, 2025, 02:15 ET Tsingke Biotech Hosts 2025 Small Nucleic Acid Therapeutics Roundtable in Beijing
Biotech Tsingke Biotech is a synthetic biology and biotech manufacturing company focused on gene and nucleic acid technologies. The company provides a wide portfolio of services including gene synthesis, oligonucleotide production, RNA therapeutics support, and GMP-compliant raw material manufacturing
More news about: Beijing Tsingke Biotech Co., Ltd.
Jul 28, 2025, 21:52 ET Raytron dévoile 4 technologies clés derrière les caméras thermiques IA pour la surveillance de sécurité 24h/24 et 7j/7
s'enfoncent dans un brouillard dense, la nuit noire ou un feuillage luxuriant ou lorsque les caméras tremblent violemment et que la densité de circulation gêne leur vue.Raytron a présenté un nouveau système de suivi IA à double spectre, combinant l'imagerie thermique à haute résolution et les caméras à lumière
More news about: Raytron Technology Co., Ltd.
Jul 28, 2025, 18:58 ET SRPT Investors Have Opportunity to Lead Sarepta Therapeutics, Inc. Securities Fraud Lawsuit
the lawsuit, throughout the Class Period, defendants made false and misleading statements and/or failed to disclose that: (1) ELEVIDYS, a prescription gene therapy intended for certain patients being treated for Duchenne muscular dystrophy, posed significant safety risks to patients; (2) ELEVIDYS trial
More news about: THE ROSEN LAW FIRM, P. A.